Urge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake
 
Report

Urge Urinary Incontinence - Poor Differentiation Limiting New Product UptakeUrge Urinary Incontinence - Poor Differentiation Limiting New Product Uptake is a marketing resource from Datamonitor, a leading provider of online data, analytic and forecasting platforms for key vertical sectors.

From:
$15200
 
Introduction

Urge urinary incontinence (UUI) is a relatively common disorder which can affect all age groups but becomes increasingly prevalent with old age. Although several pharmacological therapies are available for treating this distressing condition, patients' reluctance to present to a physician and incorrect diagnosis of the different overactive bladder subtypes limit the potential of this market.



Scope


  • Quantitative treatment data from 418 physicians based in US, Japan, France, Germany, Italy, Spain and UK; supported by key opinion leader comments
  • Analysis of epidemiology, presentation and referral patterns, diagnostic assessment, and first- to third-line treatments for UUI
  • Influences on treatment choice and perception of current drug therapies including tolterodine, oxybutynin, darifenacin and solifenacin
  • Evaluation of unmet needs and future outlook including awareness of R&D drug pipeline


  • Highlights

    Although the prevalence of UUI in women is high, the potential of this market is limited by the reluctance of patients to present to a physician for treatment. Direct to consumer advertising, where available, has already increased awareness and presentation of this condition but other strategies are also required to assist in enlarging the market.



    In theory, UUI could be managed successfully by PCPs. However, there is little belief in their ability to correctly diagnose the subtypes of OAB and this lack of confidence is supported by inappropriate prescribing trends by PCPs. Methods to address diagnosis and treatment of UUI in the primary care setting should reflect the priorities of PCPs.



    Older treatments for UUI are associated with a number of unpleasant side effects, leaving significant unmet need in this market. Several new products have recently entered the market yet there is little perceived differentiation from existing treatments. Emphasizing the improved efficacy and side effect profiles is key to improving uptake.



    Reasons to Purchase

  • Forecast product sales by understanding key aspects of UUI epidemiology, diagnosis and treatment
  • Gain a better understanding of the challenges facing current and future players in the UUI market
  • Identify physicians key concerns in UUI including unmet needs and the attributes that physicians believe are desirable for future treatments
Report Details:
Publisher:
Datamonitor
Type:
Market Study - April 2006
Number of pages:
42
First Publication Date:
14/4/2006
 
 
 
Copyright © Chiltern Magazine Services Ltd | Email: admin@cmsinfo.com | Tel: +(1) 508 861 0401